[肺腺癌的分子病理学,EGFR T790M抗性突变研究]
Andrea Kohánka1, László Báthory-Fülöp1, Eszter Tanács-Bencze1
1Sebészeti és Molekuláris Patológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary. dr.toth.erika@oncol.hu.
Magyar onkologia
|December 10, 2024
概括
在肺癌患者中检测EGFR T790M耐药性突变对于有效治疗至关重要. 我们的研究发现T790M突变频率为38.3%,与之前的发现相似.
科学领域:
- 在瘤学瘤学.
- 分子诊断学 分子诊断
- 遗传学 是一个遗传学.
背景情况:
- 表皮生长因子受体 (EGFR) 氨酸激酶抑制剂 (TKI) 治疗是EGFR突变肺腺癌的标准治疗方法.
- 对一线和二线EGFRTKI获得的耐药性通常涉及T790M突变.
- 早期识别T790M突变可以使用第三代技术知识.
研究的目的:
- 在肺腺癌患者中评估EGFR T790M抗性突变的频率.
- 为了比较2022年1月至2024年8月之间的T790M突变检测率和之前的时期 (2019-2021年).
- 评估再活检率对突变检测的影响.
主要方法:
- 分析了来自222名患者的380个样本,主要是血液.
- 使用超级ARMS EGFR 突变检测套件 (AmoyDx) 进行测试.
- 将当前期间的结果与2019-2021年的历史数据进行比较.
主要成果:
- 在57%的原发性瘤样本中检测到EGFR突变.
- 在所有样本中的38.3%中发现了T790M耐药性突变.
- 突变检测率与之前的研究期相比相当.
结论:
- 观察到的T790M突变频率与之前的发现一致.
- 稳定的复苏率可以解释突变检测百分比.
- 对T790M的持续监测对于指导肺癌治疗至关重要.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
相关概念视频
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
